Starlight Therapeutics

Starlight Therapeutic is an emerging precision oncology company focused solely on CNS (central nervous system) cancers, primarily brain cancers. It is estimated that there are over 120 subtypes of CNS cancers that have a devastating impact on adult and pediatric populations. Most of these CNS cancers do not have effective therapies and current treatment relies on a combination of surgery, radiotherapy, and chemotherapy. There is a significant need for new therapeutic options to improve patient outcomes. Starlight is developing our lead drug candidate, known as STAR-001, for some of the most unaddressed brain cancers. STAR-001, we believe, has the potential to be effective in both primary and secondary (metastatic) brain cancers as demonstrated in multiple preclinical cancer models. Starlight’s initial focus is developing STAR-001 for CNS cancers including adult glioblastoma, adult brain metastases, and pediatric brain cancers such as atypical teratoid rhabdoid tumors (ATRT).